Revance Therapeutics, Inc. - Understand $rvnc stock

$RVNC Market Cap: $413.3 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$247.0M

TTM

Gross Margin

72.46%

TTM

Net Earnings

-$184.5M

TTM

Current Assets

$329.7M

Q3 2024

Current Liabilities

$80.05M

Q3 2024

Current Ratio

411.86%

Q3 2024

Total Assets

$461.6M

Q3 2024

Total Liabilities

$624.6M

Q3 2024

Book Value

-$163.0M

Q3 2024

Cash

$58.59M

Q3 2024

P/E

-2.240

Nov 29, 2024 EST

Free Cash Flow

-$194.9M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$234.0M	$132.6M	$77.80M	$15.33M	$413.0K	$3.729M	$262.0K	$300.0K	$300.0K	$383.0K	$617.0K	$150.0K	$560.0K
YoY Change	76.55%	70.4%	407.65%	3610.65%	-88.92%	1323.28%	-12.67%	0.0%	-21.67%	-37.93%	311.33%	-73.21%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$234.0M	$132.6M	$77.80M	$15.33M	$413.0K	$3.729M	$262.0K	$300.0K	$300.0K	$383.0K	$617.0K	$150.0K	$560.0K
Cost Of Revenue	$74.36M	$51.67M	$23.41M	$4.770M							$0.00	$0.00	$10.00K
Gross Profit	$159.7M	$80.90M	$54.39M	$10.56M							$620.0K	$720.0K	$550.0K
Gross Profit Margin	68.23%	61.03%	69.91%	68.91%							100.49%	480.0%	98.21%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$297.7M	$223.9M	$198.8M	$151.8M	$62.01M	$53.86M	$37.40M	$29.08M	$25.09M	$19.04M	$11.01M	$12.36M	$5.560M
YoY Change	32.96%	12.63%	30.94%	144.87%	15.13%	44.03%	28.63%	15.89%	31.74%	72.95%	-10.89%	122.23%
% of Gross Profit	186.46%	276.81%	365.56%	1437.94%							1775.97%	1716.11%	1010.91%
Research & Development	$79.41M	$101.3M	$116.3M	$125.8M	$102.9M	$92.50M	$80.36M	$50.38M	$47.53M	$33.39M	$27.83M	$19.56M	$22.74M
YoY Change	-21.6%	-12.88%	-7.58%	22.3%	11.2%	15.11%	59.51%	6.0%	42.35%	19.97%	42.31%	-14.0%
% of Gross Profit	49.73%	125.2%	213.75%	1191.24%							4488.87%	2716.25%	4134.55%
Depreciation & Amortization	$11.38M	$33.73M	$19.85M	$10.25M	$2.909M	$1.726M	$1.468M	$1.445M	$1.995M	$2.100M	$1.881M	$1.777M	$1.980M
YoY Change	-66.28%	69.91%	93.69%	252.35%	68.54%	17.57%	1.59%	-27.57%	-5.0%	11.64%	5.85%	-10.25%
% of Gross Profit	7.12%	41.7%	36.5%	97.06%							303.39%	246.81%	360.0%
Operating Expenses	$377.1M	$325.2M	$315.1M	$277.6M	$164.9M	$146.4M	$120.7M	$88.52M	$72.62M	$52.43M	$38.84M	$31.91M	$28.29M
YoY Change	15.97%	3.22%	13.48%	68.4%	12.65%	21.28%	36.35%	21.89%	38.49%	34.99%	21.71%	12.81%
Operating Profit	-$316.8M	-$342.0M	-$274.7M	-$273.2M	-$164.5M	-$142.6M	-$120.4M	-$88.22M	-$72.32M	-$52.05M	-$38.23M	-$31.76M	-$27.74M
YoY Change	-7.36%	24.5%	0.55%	66.1%	15.3%	18.44%	36.51%	21.98%	38.94%	36.17%	20.34%	14.5%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$19.36M	$16.47M	$6.273M	$15.15M	$0.00	$44.00K	$457.0K	$1.082M	$1.190M	$10.67M	$15.16M	$444.0K	-$17.30M
YoY Change	17.49%	162.62%	-58.59%		-100.0%	-90.37%	-57.76%	-9.08%	-88.85%	-29.62%	3315.32%	-102.57%
% of Operating Profit
Other Income/Expense, Net	-$838.0K	-$2.181M	-$759.0K	-$592.0K	-$303.0K	-$773.0K	-$525.0K	-$535.0K	-$327.0K	-$234.0K	-$404.0K	-$123.0K	$170.0K
YoY Change	-61.58%	187.35%	28.21%	95.38%	-60.8%	47.24%	-1.87%	63.61%	39.74%	-42.08%	228.46%	-172.35%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$323.7M	-$355.7M	-$281.3M	-$284.7M	-$159.4M	-$139.6M	-$118.3M	-$89.27M	-$73.48M	-$62.92M	-$52.45M	-$58.26M	-$44.86M
YoY Change	-9.01%	26.45%	-1.19%	78.58%	14.23%	17.95%	32.55%	21.5%	16.78%	19.96%	-9.97%	29.87%
Income Tax	$300.0K	$700.0K	$0.00	-$2.620M	$0.00	$3.000M	$0.00	$0.00			$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$324.0M	-$356.4M	-$281.3M	-$282.1M	-$159.4M	-$142.6M	-$120.6M	-$89.30M	-$73.50M	-$62.90M	-$52.40M	-$32.21M	-$44.86M
YoY Change	-9.09%	26.7%	-0.28%	76.94%	11.83%	18.23%	35.04%	21.5%	16.85%	20.04%	62.7%	-28.21%	53.49%
Net Earnings / Revenue	-138.44%	-268.85%	-361.58%	-1840.71%	-38602.66%	-3823.22%	-46025.57%	-29766.67%	-24500.0%	-16422.98%	-8492.71%	-21471.33%	-8011.25%
Basic Earnings Per Share	-$3.83	-$4.90	-$4.17	-$4.86	-$3.67				-$3.02	-$3.24	$1.17	-$1.37
Diluted Earnings Per Share	-$3.83	-$4.90	-$4.17	-$4.86	-$3.67	-$3.942M	-$4.006M	-$3.176M	-$3.02	-$3.24	$1.05	-$1.37	-$2.529M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$253.9M	$340.7M	$225.1M	$436.5M	$290.1M	$175.8M	$282.9M	$185.5M	$252.3M	$171.0M	$3.900M	$4.100M	$29.60M
YoY Change	-25.47%	51.38%	-48.44%	50.47%	65.02%	-37.86%	52.51%	-26.48%	47.54%	4284.62%	-4.88%	-86.15%
Cash & Equivalents	$137.3M	$109.0M	$110.6M	$333.6M	$171.2M	$73.30M	$282.9M	$63.50M	$201.6M	$171.0M	$3.900M	$4.100M	$29.60M
Short-Term Investments	$116.6M	$231.7M	$114.4M	$102.9M	$119.0M	$102.6M	$0.00	$122.0M	$50.70M
Other Short-Term Assets	$11.70M	$4.356M	$7.544M	$5.800M	$6.500M	$5.100M	$2.200M	$1.200M	$1.500M	$1.400M	$600.0K	$1.300M	$500.0K
YoY Change	168.48%	-42.26%	30.07%	-10.77%	27.45%	131.82%	83.33%	-20.0%	7.14%	133.33%	-53.85%	160.0%
Inventory	$45.58M	$18.33M	$10.15M	$5.900M
Prepaid Expenses
Receivables	$27.68M	$11.34M	$3.348M	$1.800M	$0.00	$27.00M	$0.00	$100.0K	$200.0K	$300.0K	$200.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$5.900M	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$338.9M	$374.7M	$246.1M	$450.0M	$296.6M	$207.9M	$285.2M	$192.7M	$254.0M	$172.7M	$4.800M	$5.400M	$30.10M
YoY Change	-9.57%	52.26%	-45.31%	51.72%	42.66%	-27.1%	48.0%	-24.13%	47.08%	3497.92%	-11.11%	-82.06%
Property, Plant & Equipment	$90.21M	$67.76M	$69.00M	$47.10M	$41.30M	$14.40M	$9.300M	$10.60M	$19.70M	$19.30M	$14.30M	$7.000M	$8.400M
YoY Change	33.14%	-1.81%	46.5%	14.04%	186.81%	54.84%	-12.26%	-46.19%	2.07%	34.97%	104.29%	-16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments								$0.00	$1.800M
YoY Change								-100.0%
Other Assets	$39.57M	$35.24M	$13.75M	$4.800M	$2.400M	$4.000M	$1.200M	$1.100M	$400.0K	$500.0K	$3.500M	$1.000M	$1.400M
YoY Change	12.3%	156.34%	186.4%	100.0%	-40.0%	233.33%	9.09%	175.0%	-20.0%	-85.71%	250.0%	-28.57%
Total Long-Term Assets	$139.6M	$207.2M	$285.0M	$270.2M	$43.70M	$18.40M	$10.50M	$11.70M	$21.80M	$19.80M	$17.80M	$8.000M	$9.800M
YoY Change	-32.62%	-27.32%	5.49%	518.31%	137.5%	75.24%	-10.26%	-46.33%	10.1%	11.24%	122.5%	-18.37%
Total Assets	$478.5M	$581.9M	$531.2M	$720.2M	$340.3M	$226.3M	$295.7M	$204.4M	$275.8M	$192.5M	$22.60M	$13.40M	$39.90M
YoY Change
Accounts Payable	$13.81M	$4.546M	$10.60M	$12.70M	$8.000M	$8.400M	$6.800M	$3.800M	$2.700M	$3.100M	$5.500M	$1.800M	$800.0K
YoY Change	203.76%	-57.13%	-16.51%	58.75%	-4.76%	23.53%	78.95%	40.74%	-12.9%	-43.64%	205.56%	125.0%
Accrued Expenses	$56.34M	$57.04M	$42.86M	$35.90M	$21.90M	$14.40M	$11.50M	$11.80M	$5.500M	$3.700M	$3.600M	$5.600M	$2.700M
YoY Change	-1.22%	33.07%	19.39%	63.93%	52.08%	25.22%	-2.54%	114.55%	48.65%	2.78%	-35.71%	107.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.151M	$669.0K				$0.00	$1.900M	$3.500M	$3.100M	$2.900M	$22.90M	$95.40M	$4.600M
YoY Change	669.96%					-100.0%	-45.71%	12.9%	6.9%	-87.34%	-76.0%	1973.91%
Total Short-Term Liabilities	$89.22M	$75.68M	$67.29M	$61.00M	$41.00M	$32.00M	$20.90M	$19.60M	$12.00M	$10.20M	$47.60M	$117.9M	$8.900M
YoY Change	17.89%	12.47%	10.31%	48.78%	28.13%	53.11%	6.63%	63.33%	17.65%	-78.57%	-59.63%	1224.72%
Long-Term Debt	$426.6M	$379.4M	$280.6M	$180.5M	$0.00	$0.00	$0.00	$1.900M	$5.300M	$600.0K	$3.900M	$11.40M	$64.90M
YoY Change	12.45%	35.18%	55.48%				-100.0%	-64.15%	783.33%	-84.62%	-65.79%	-82.43%
Other Long-Term Liabilities	$114.2M	$114.2M	$114.8M	$104.4M	$73.80M	$48.80M	$6.000M	$5.800M	$5.200M	$5.300M	$4.800M	$5.400M	$26.20M
YoY Change	0.0%	-0.46%	9.93%	41.46%	51.23%	713.33%	3.45%	11.54%	-1.89%	10.42%	-11.11%	-79.39%
Total Long-Term Liabilities	$540.8M	$493.6M	$395.4M	$284.9M	$73.80M	$48.80M	$6.000M	$7.700M	$10.50M	$5.900M	$8.700M	$16.80M	$91.10M
YoY Change	9.57%	24.84%	38.79%	286.04%	51.23%	713.33%	-22.08%	-26.67%	77.97%	-32.18%	-48.21%	-81.56%
Total Liabilities	$630.1M	$569.3M	$462.7M	$345.9M	$114.8M	$80.70M	$26.90M	$27.30M	$22.60M	$16.10M	$56.20M	$134.7M	$100.0M
YoY Change	10.67%	23.04%	33.76%	201.31%	42.26%	200.0%	-1.47%	20.8%	40.37%	-71.35%	-58.28%	34.7%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2015	2014	2013	2012
Basic Shares Outstanding	84.60M shares	72.71M shares	67.51M shares	58.01M shares	43.46M shares	24.34M shares	19.39M shares	220.2K shares	23.56M shares
Diluted Shares Outstanding	84.60M shares	72.71M shares	67.51M shares	58.01M shares	43.46M shares	24.34M shares	19.39M shares	1.029M shares	23.56M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $413.32 Million

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 597 full-time employees. The company went IPO on 2014-02-06. The firm's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. The company has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The firm has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.

Industry: Pharmaceutical Preparations Peers: Amylyx Pharmaceuticals, Inc. Axsome Therapeutics, Inc. CASSAVA SCIENCES INC JOHNSON & JOHNSON SUPERNUS PHARMACEUTICALS, INC. Tilray Brands, Inc. Ventyx Biosciences, Inc.